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Objective:  Describe outcomes of and risk factors for endophthalmitis following 1 
intravitreal anti-VEGF injection. 2 
 3 
Design: Single-center, consecutive, case series and retrospective case-control study 4 
 5 
Participants: Between 1/1/09 and 5/31/10, 16 vitreoretinal surgeons administered a total 6 
of 27,736 injections. During this period, twenty-three cases of presumed infectious 7 
endophthalmitis occurred. Each surgeon used their own preferred injection technique.  8 
 9 
Intervention:  10 
Vitreous and/or aqueous tap with intravitreal antibiotic injection and subsequent topical 11 
antibiotic and steroid drops.   12 
 13 
Main Outcome Measures: Visual acuity, bladed lid speculum use, conjunctival 14 
displacement, hemisphere of injection, bevacizumab vs. ranibizumab, and infectious 15 
organism. 16 
 17 
Results: Seven of 23 cases were culture-positive; three grew coagulase negative 18 
Staphylococcus. All cases presented with pain and vitritis on average 3.4 days (range 1 – 19 
6) after injection, with no difference between culture-positive and culture-negative 20 
groups.  Eighteen of 23 cases (78%) had a hypopyon. 16 of 23 cases returned to baseline 21 
vision (+/- 2 lines) within three months.  Neither lid speculum use (0.10% vs. 0.066% in 22 
the no use group, p = 0.27), conjunctival displacement (0.11% vs. 0.076% no 23 
displacement, p = 0.43), hemisphere of injection (0.11% superior vs. 0.079% inferior, p = 24 
0.56), or bevacizumab vs. ranibizumab (0.11% vs 0.066%, p = 0.21) affected risk.  25 
Analysis of only culture positive results yielded similar results.  There was no statistically 26 
significant difference between the proportion of culture-negative cases after bevacizumab 27 
(83%) versus ranibizumab injection (55%, p = 0.13).    28 
 29 
Conclusion: Most patients who develop presumed infectious endophthalmitis after anti-30 
VEGF injection regained baseline vision after treatment. Bladed lid speculum use, 31 
conjunctival displacement, hemisphere of injection, and type of anti-VEGF agent did not 32 
affect risk. We did not detect a difference in culture-negative endophthalmitis rates after 33 
bevacizumab versus ranibizumab injection. Neither the presence of pain, vitritis, 34 
decreased vision, or hypopyon, nor the interval between injection and development of 35 
symptoms, differentiated culture-positive from culture-negative cases. As a subgroup of 36 
patients have poor outcomes, a low threshold for vitreous tap with intravitreal antibiotic 37 
injection may be warranted. 38 
 39 
 40 
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Introduction: 1 
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have 2 
revolutionized the treatment of neovascular age-related macular degeneration (AMD).  3 
The use of these medications continues to increase as their indications expand, including 4 
for diseases such as retinal vein occlusions1, 2, neovascular glaucoma3, and diabetic 5 
macular edema4.   6 
Infectious endophthalmitis remains one of the most feared complications of 7 
intravitreal injections.  Endophthalmitis can lead to apoptosis of ganglion cells, bipolar 8 
cells, and photoreceptors5, or to retinal detachment, which can all lead to significant 9 
vision loss or to loss of the eye.   10 
Few clinical studies describe visual outcomes after post-injection 11 
endophthalmitis6-8 or identify modifiable risk factors to prevent infection.  Further, there 12 
is debate regarding the clinical distinction between infectious and non-infectious 13 
endophthalmitis, with some authors positing that absence of pain supports a non-14 
infectious etiology9, 10.  This study evaluates a large series of endophthalmitis cases 15 
developing after anti-VEGF injection and assesses outcomes and risk factors. 16 
 17 
Patients and Methods 18 
Overview: 19 
Institutional Review Board approval was obtained from Wills Eye Institute. 20 
During an infection surveillance program, the authors prospectively recorded cases of 21 
endophthalmitis occurring after intravitreal injection of bevacizumab or ranibizumab 22 
between January 1, 2009 and May 31, 2010.  Charts from these cases were 23 
retrospectively reviewed at the conclusion of the surveillance period.  All injections were 24 
performed at a single, retina-only practice by 16 different vitreoretinal specialists with 16 25 
different offices.  The total number of intravitreal bevacizumab and ranibizumab 26 
injections was determined using billing data, allowing a retrospective case-control 27 
analysis for risk factors.  28 
 29 
Injection technique: 30 
All eyes were prepped in a standardized fashion.  Briefly, eyes were anesthetized 31 
with topical drops (e.g., proparacaine 0.5% [Ophthetic, Allergan, Inc.]), a topical 32 
antibiotic (e.g., ofloxacin 0.3% [Ocuflox, Allergan, Inc.]), topical 5% povidone-iodine 33 
(Betadyne, Alcon Labs), viscous anesthetic (e.g., tetracaine solution 0.5% [TetraVisc, 34 
OCuSoft, Inc.]), and another drop of topical 5% povidone-iodine prior to injection.  35 
Rarely, subconjunctival lidocaine 2% was substituted for viscous anesthesia.  The 36 
eyelashes were not prepped and a sterile drape was not used.  Pre-injection antibiotics 37 
were not used.   38 
Each vitreoretinal specialist administered anti-VEGF injections through the pars 39 
plana, 3.5 – 4.0 mm from the limbus with a 30- or 31-gauge needle using his or her 40 
preferred technique.  Physicians were asked to consistently use his or her preferred 41 
injection technique for the duration of the infection surveillance period, and periodic 42 
monitoring was performed to ascertain whether there was identifiable change in 43 
technique.  Variables included bladed lid speculum use, conjunctival displacement with a 44 
sterile cotton tip applicator prior to injection, and superior versus inferior hemisphere of 45 
injection.  Physicians not using a lid speculum employed variable techniques to expose 46 
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the globe, including gloved or ungloved fingers to open the lids, an assistant’s gloved or 1 
ungloved fingers, or simply instructed patients to open their eyelids widely.  Those not 2 
displacing conjunctiva with a cotton tip applicator injected straight through conjunctiva 3 
and sclera into the vitreous.  Patients were prescribed a topical antibiotic to use four times 4 
a day for four days post-injection.  The specific antibiotic was per the preference of the 5 
injecting physician. 6 
 7 
Tap and inject protocol: 8 
 All eyes that developed presumed infectious endophthalmitis were sent to Wills 9 
Eye Institute for immediate tap of the vitreous through the pars plana with injection of 10 
intravitreal antibiotics (tap and inject).  No patients were treated at satellite offices.  The 11 
vitreous tap consisted of insertion of a 25-gauge needle into the vitreous cavity with 12 
attempted aspiration of vitreous in all patients.  If adequate vitreous fluid was unable to 13 
be obtained, an aqueous tap was performed.  All samples were sent to the department of 14 
microbiology at Thomas Jefferson University Hospital, Philadelphia, PA, for gram stain, 15 
cultures, and sensitivities.  Patients then received intravitreal vancomycin (1 mg/0.1 mL) 16 
and intravitreal ceftazidime (2 mg/0.1 mL).  Penicillin allergic patients received 17 
intravitreal amikacin (400 mcg/0.1 mL) instead of intravitreal ceftazidime.  All patients 18 
were then placed on fortified vancomycin (25 mg/mL), fortified tobramycin (15 mg/mL), 19 
and prednisolone acetate 1% drops every hour, as well as atropine sulfate 1% drops twice 20 
a day.  Patients were followed daily until they had evidence of clinical improvement, at 21 
which time the drops were slowly tapered and examination intervals were gradually 22 
extended.  Antibiotic drops also were modified based on culture sensitivity data.   23 
 24 
Inclusion and exclusion criteria: 25 
All eyes with presumed infectious endophthalmitis warranting tap and inject were 26 
included in this case series.  The criteria for tap and inject were dependent on the 27 
judgment of individual vitreoretinal specialists, but universally included decreased visual 28 
acuity, the presence of pain, and the presence of vitritis within one week of intravitreal 29 
anti-VEGF injection.  Patients not included in this case series were those with mild post-30 
injection anterior chamber inflammation (1+ or less), who improved on topical 31 
corticosteroid and antibiotic drops without undergoing tap and inject.   32 
 33 
Endophthalmitis surveillance log: 34 
One researcher (CPS) recorded data for all patients undergoing tap and inject in 35 
an infection surveillance log.  These data included the presence of pain, vitritis, and/or 36 
hypopyon, visual acuity before the causative injection and at time of tap and inject 37 
(Snellen acuity, not best corrected), date of causative anti-VEGF injection, date of tap 38 
and inject, office location, injecting vitreoretinal surgeon, type of anti-VEGF injection 39 
(bevacizumab versus ranibizumab), lot number, underlying retinal diagnosis, number of 40 
prior anti-VEGF injections, lens status, source of tap (vitreous or aqueous), identified 41 
organism, and antibiotic specificities.  At the end of the surveillance period, charts were 42 
retrospectively reviewed to collect follow-up data. 43 
 44 
Analysis of case series and case-control study: 45 
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Clinical variables of presumed infectious endophthalmitis were analyzed using 1 
Excel (Microsoft, Redmond, WA).  These features included the presence of pain, 2 
hypopyon, vitritis, decreased vision, and duration between causative anti-VEGF injection 3 
and tap and inject.  Outcome data included return of baseline visual acuity (plus or minus 4 
two lines of Snellen acuity, not best-corrected) and need for pars plana vitrectomy. 5 
To evaluate risk factors for developing endophthalmitis, the authors conducted a 6 
retrospective case-control analysis.  The total number of bevacizumab and ranibizumab 7 
injections administered was determined using billing data.  The number of anti-VEGF 8 
injections was also stratified by office location and injecting vitreoretinal surgeon.  9 
Several risk factors for presumed infectious endophthalmitis after anti-VEGF injection 10 
were examined.  These included bladed lid speculum use, conjunctival displacement with 11 
a sterile cotton tip applicator prior to injection, superior versus inferior hemisphere of 12 
injection, the use of bevicizumab versus ranibizumab, office location, injecting 13 
vitreoretinal specialist, and lot number of the specific anti-VEGF agent.  A two-sample 14 
test of proportion was performed using Stata 9 (College Park, TX).  Analysis was done 15 
for all cases of presumed infectious endophthamitis and further stratified for culture-16 
positive and culture-negative cases. 17 
  18 
Results 19 
 20 
Clinical Features 21 
 During the 17-month study period, a total of 27,736 consecutive intravitreal anti-22 
VEGF injections were administered, including 10,958 bevacizumab and 16,778 23 
ranibizumab injections.  Twenty-three of these cases underwent emergent tap and inject 24 
for presumed infectious endophthalmitis (0.083%, 95% confidence interval 0.049% to 25 
0.12%).  Twenty-one of these eyes received anti-VEGF injection for neovascular AMD, 26 
while two were treated for macular edema secondary to branch retinal vein occlusion. 27 
All cases of presumed infectious endophthalmitis presented with pain, vitritis, and 28 
decreased visual acuity.  Most cases had a hypopyon at time of tap and inject (18 of 23 29 
eyes, 78%).  Five of seven culture-positive cases presented with hypopyon (71%, 30 
p=XXX).   31 
There was an average of 3.4 days (range 1 to 6 days) between administration of 32 
anti-VEGF injection and emergent tap and inject.  This average was similar between 33 
culture-negative (3.5 days, range 1 to 6 days) and culture-positive cases (3.1 days, range 34 
1 to 5 days, p = 0.54).  One culture-negative case presenting 17 days after injection was 35 
excluded from this analysis because the patient’s nursing home delayed seeking medical 36 
attention.   37 
Vitreous tap was performed in all cases, and an adequate specimen was obtained 38 
in 14 of 23 cases. When the vitreous tap was unsuccessful, an aqueous tap was performed 39 
successfully in the remaining 9 of 23 cases.  An infectious organism was identified from 40 
vitreous and/or aqueous biopsy in 30.4% of patients (7 of 23), for a culture-positive 41 
endophthalmitis rate of 0.025% per injection.  Causative organisms included three cases 42 
of coagulase negative staphylococci, and one case of each Staphylococcus aureus, 43 
Streptococcus viridans, Streptococcus mitus, and Enterococcus faecalis.  44 
 45 
Visual Outcomes  46 
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 Most cases (16 of 23, 70%) returned to baseline vision (+/- 2 lines) within three 1 
months (see Table 1, available at http://aaojournal.org).  Four more cases returned to 2 
baseline vision at six months; a total of 83% of cases had recovery of baseline vision.  3 
Specifically, the three eyes that did not return to baseline were as follows: the vision of 4 
one patient dropped from 20/300 to no light perception after retinal detachment with 5 
subsequent retinal detachment repair, one from 20/40 to counting fingers after retinal 6 
detachment repair, one from 20/400 to counting fingers, and one from 20/50 to 20/100.  7 
Four of 23 cases (17%) underwent pars plana vitrectomy three days to 3 weeks after 8 
initial tap and inject for retinal detachment, vitreous hemorrhage, or worsening 9 
endophthalmitis.   10 
Of the seven culture-positive cases, four returned to baseline vision by three 11 
months and an additional case returned by six months (71%). Of the two culture-positive 12 
eyes not returning to baseline vision, both underwent subsequent pars plana vitrectomy 13 
for retinal detachment.  These eyes grew Streptococcus viridans and Streptococcus mitus, 14 
respectively.  15 
Of the 16 culture-negative cases, 13 returned to baseline vision by three months 16 
with another two returning by six months (94%). There was no significant difference in 17 
the visual recovery rate between culture positive and culture-negative cases (p = 0.14).Of 18 
note, one patient developed pain, decreased vision, and hypopyon twice after sequential 19 
bevacizumab injection (patient’s third and fourth injections).  During the first episode, the 20 
patient underwent tap and inject three days after causative bevacizumab injection and 21 
improved to baseline visual acuity at six weeks.  During the second episode, the patient 22 
was treated initially with hourly prednisolone acetate drops and had continued worsening 23 
of inflammation.  The patient underwent tap and inject three days after causative 24 
bevacizumab injection, and did not regain baseline visual acuity at six months.  This eye 25 
was counted twice, once for each episode.   26 
 27 
Risk Factors 28 
 Cases of endophthalmitis occurred in nine of 16 offices by nine of 16 injecting 29 
vitreoretinal surgeons.  There were no clusters of endophthalmitis with any individual 30 
treating physician or in any particular office location.  There were no trends associated 31 
with lot numbers of bevacizumab or ranibizumab injections.  32 
 No modifiable risk factors were identified (see Table 2).  Neither lid speculum use 33 
[0.10% (13 of 12,500) vs. 0.066% (10 of 15,236) in the no use group, p = 0.27, 95% 34 
confidence interval of the difference -0.031 to 0.11%], conjunctival displacement [0.11% 35 
(6 of 5,421) vs. 0.076% (17 of 22,315) no displacement, p = 0.43, 95% confidence 36 
interval of the difference -0.061 to 0.13%],], hemisphere of injection [0.11% (4 of 3,683) 37 
superior vs. 0.079% (19 of 24,053) inferior, p = 0.56, 95% confidence interval of the 38 
difference -0.082 to 0.14%],], or bevacizumab (0.11%, 12 of 10,958) vs. ranibizumab 39 
(0.066%, 11 of 16,778, p = 0.21, 95% confidence interval of the difference -0.030 to 40 
0.12%],) affected risk.  Results were similar with analysis of only culture-positive cases 41 
[0.032% (4 of 12,500) vs. 0.020% (3 of 15,236) in the no speculum group (p = 0.52), 42 
0.018% (1 of 5,421) vs. 0.027% (6 of 22,315) in the no conjunctival displacement group 43 
(p = 0.73), 0.054% (2 of 3,683) superior vs. 0.021% (5 of 24,053) inferior hemisphere of 44 
injection (p = 0.23), and 0.018% (2 of 10,958) post-bevacizumab vs. 0.030% (5 of 45 
16,778) post-ranibizumab (p = 0.55)]. The proportion of culture-negative cases was 46 
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similar after bevacizumab (83%, 10 of 12) and ranibizumab injection (55%, 6 of 11, p = 1 
0.13).   2 
 Power calculations revealed that 101,958 injections evenly split between two 3 
groups would be needed to detect a difference between 0.05% and 0.10% with an alpha 4 
of 0.05 and a beta of 0.20.   5 
   6 
Discussion 7 
  This large, single-center cases series and case-control study evaluated cases with 8 
presumed infectious endophthalmitis occurring after intravitreal anti-VEGF injection. 9 
Overall, we detected 23 cases of endophthalmitis after 27,736 injections for an incidence 10 
of 0.083%.  All cases presented with pain, decreased visual acuity, and vitritis three to 11 
four days after intravitreal anti-VEGF injection; most eyes had hypopyon.  These features 12 
did not help distinguish between culture-positive and culture-negative cases.  Most cases 13 
returned to baseline visual acuity within three to six months, though some suffered 14 
significant visual loss.  There were no modifiable risk factors for post-injection 15 
endophthalmitis, including the use of a bladed lid speculum, conjunctival displacement 16 
with a sterile cotton tip applicator, superior versus inferior hemisphere of injection, and 17 
the use of bevacizumab versus ranibizumab. 18 
The reported rates of endophthalmitis after intravitreal anti-VEGF injection vary 19 
between institutions, study designs, and definitions of endophthalmitis.  Our rate is 20 
consistent with other large prospective trials.  The Minimally Classic/Occult Trial of the 21 
Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) 22 
study reported an endophthalmitis incidence of 0.05% (5 cases per 10,443 injections) 11, 23 
identical to the rate reported in the Anti-VEGF Antibody for the Treatment of 24 
Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) study12, 13 (3 25 
cases per 5,921 injections).  However, 14 patients in the MARINA trial and 10 patients in 26 
the ANCHOR trial experienced 2+ to 4+ inflammation on slit-lamp examination and 27 
were not treated for presumed endophthalmitis.  In contrast, at our institution, nearly all 28 
patients who develop vitritis, or who develop significant anterior chamber cellular 29 
reaction, would be given intravitreal antibiotics. Including these untreated patients, the 30 
clinically presumed endophthalmitis rate increases to 0.18% in the MARINA trial and 31 
0.22% in the ANCHOR trial.  It is possible that our study includes eyes with post-32 
injection inflammation that would have been observed in the MARINA and ANCHOR 33 
trials. 34 
Endophthalmitis rates in retrospective studies vary tremendously.  Fintak and 35 
colleagues14 identified cases of endophthalmitis from billing records at four institutions, 36 
reporting a rate of 0.02% (6 of 26,905 injections).  All injecting physicians used a lid 37 
speculum and 5% to 10% topical povidone-iodine drops to disinfect the ocular surface; 38 
some physicians used 10% povidone-iodine soaked swabs to clean the eyelid skin, 39 
eyelashes, and lid margin.  Pilli and colleagues8 also reported a similarly low rate of post-40 
injection endophthalmitis in an office setting (0.029%, 3 of 10,254 injections).  In this 41 
study, the authors retrospectively collected endophthalmitis cases by reviewing case 42 
notes and from conversations with referral sources and other vitreoretinal groups in the 43 
area.  Patients were prepped with 5% povidone-iodine drops.  A lid speculum was used 44 
based on the surgeon’s discretion.  In both of these studies, the retrospective study design 45 
could have missed endophthalmitis cases, underestimating the incidence of this rare 46 
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complication.  At the other end of the spectrum, Fong and colleagues15 reported a 10-fold 1 
higher rate of endophthalmitis in a retrospective study of intravitreal bevacizumab and 2 
ranbizumab injections (0.26%, 4 of 1,553 total injections), collecting cases from an AMD 3 
registry amassed from injection logs.  Details were not given regarding the injection 4 
technique. 5 
Non-infectious endophthalmitis, or uveitis, has been reported after intravitreal 6 
anti-VEGF injection, particularly after bevacizumab injection9, 10, 16, 17.  In our study, 7 
however, the proportion of culture-negative—and possibly non-infectious—8 
endophthalmitis cases was similar after bevacizumab and ranibizumab injections.   9 
Prior studies have offered clinical criteria to distinguish between culture-positive 10 
and culture-negative endophthalmitis.  Ness and colleagues9 reported 10 cases of uveitis, 11 
termed toxic vitritis, after bevacizumab injection.  They felt the timing and severity of 12 
pain helped distinguish it from infectious endophthalmitis.  All toxic vitritis cases 13 
presented within 48 hours with mild to no pain.  A hypopyon was not a distinguishing 14 
feature; six cases of toxic vitritis presented with hypopyon.  The authors attributed these 15 
cases to a toxic reaction from the brand of syringe used for injection.  Georgopoulos and 16 
colleagues10 reported eight cases of non-infectious endophthalmitis after bevacizumab.  17 
All cases presented within two days of injection without hypopyon.  Only one patient had 18 
pain.  Mezad-Koursh and colleagues found that later presentation, pain, keratic 19 
precipitates, fibrin, hypopyon, and anterior synechiae were more typical of culture 20 
positive endophthalmitis18.  21 
 In contrast, our study suggests that one cannot clinically distinguish  between 22 
culture-positive and culture-negative endophthalmitis after anti-VEGF injection.  All 23 
cases in our series had pain, decreased vision, and vitritis.  Both culture-positive and 24 
culture-negative cases presented an average of three to four days after injection.  Most 25 
patients in both groups had a hypopyon.  Anecdotally, one case of endophthalmitis due to 26 
Streptococcus viridans with a final visual acuity of no light perception initially presented 27 
two days after injection with 3+ cell and no hypopyon.  Another patient presented with 28 
sequential hypopyon endophthalmitis after bevacizumab.  The first episode resolved to 29 
baseline visual acuity six weeks after tap and inject.  The second episode did not improve 30 
with hourly topical prednisolone acetate, and required tap and inject to control the 31 
inflammation; the vision never returned to baseline visual acuity at six months.  We 32 
suggest that presumed infectious endophthalmitis should be considered in all instances 33 
with post-injection inflammation in the vitreous cavity greater than 1+ cell, and strong 34 
consideration should be given to treating these cases with emergent tap and injection of 35 
intravitreal antibiotics. 36 
 Although most cases with endophthalmitis after intravitreal anti-VEGF injection 37 
returned to baseline visual acuity within three to six months, 17% lost more than two 38 
lines at final follow-up.  These outcomes are similar to those reported by Klein and 39 
colleagues6, and worse than those in other smaller studies8, 19.  There was no significant 40 
difference in rates of visual recovery between culture-positive and culture-negative cases.  41 
Only a small percentage of cases (17%) required pars plana vitrectomy.  42 
Several authors have emphasized the role of specific aspects of prepping 43 
technique to prevent endophthalmitis after intravitreal injection. The only proven 44 
endophthalmitis prophylaxis remains topical povidone-iodine to sterilize the ocular 45 
surface20, 21.  It is important to sterilize the ocular surface with povidone-iodine before 46 
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applying a viscous anesthetic; viscous gel can form a barrier preventing povidone-iodine 1 
from coming in contact with conjunctival bacteria22, 23.  Further, physicians and patients 2 
should avoid talking, coughing, and sneezing during anti-VEGF injection administration 3 
to prevent contamination with oral flora24, 25.  Streptococcus species isolates, bacteria 4 
commonly found in oral flora and isolated in two of our cases, occur three to four times 5 
more frequent in endophthalmitis after intravitreal injection than after intraocular 6 
surgery24, 25.  7 
The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial26 8 
investigators felt the risk of post-injection endophthalmitis could be modified by 9 
vigilance to an aseptic injection technique.  Their initial endophthalmitis rate was 0.18% 10 
per injection (13 cases in 7,171 injections).  After amending the injection protocol to 11 
include a sterile drape and an additional pre-injection antibiotic or povidone-iodine flush, 12 
rates decreased to 0.04% (2 of 4,465) at centers adopting the amended protocol.  They 13 
attributed 75% of cases (9 of 12) to the failure of using a lid speculum.  Many authors 14 
recommend use of a bladed lid speculum27-30, though this recommendation is based on 15 
the theoretical benefit of covering the eyelashes and eyelids from touching the needles 16 
and injection site, and not on empiric evidence.  Others argue that insertion of a lid 17 
speculum can massage secretions from meibomian glands, thus contaminating the ocular 18 
surface30. Mason and colleagues31 recently reported in a prospective masked randomized 19 
trial of 174 patients undergoing intravitreal injection that lid speculum use did not result 20 
in an increase in conjunctival bacterial counts (paired t-test, p=0.9455).  Our study found 21 
no difference in endophthalmitis rates when comparing injections administered with and 22 
without a bladed lid speculum.  All of the studies to date, including ours with a relatively 23 
large sample size, are underpowered to detect smaller differences in the rate of 24 
endophthalmitis due to the low incidence of endophthalmitis. Over 100,000 injections 25 
would need to be administered in order to find a difference in endophthalmitis rate of 26 
0.05% and 0.10%. 27 
 There is some debate as to the whether hemisphere or quadrant of injection affects 28 
endophthalmitis rates.  Superior hemisphere injections tend to be covered by the upper 29 
eyelid, away from a potentially contaminated lid margin and meibomian glands.  30 
Additionally, this location allows masking of incidental subconjunctival hemorrhage by 31 
the upper eyelid.  The disadvantage of superior hemisphere injections is the difficulty of 32 
administering the injection when patients attempt to squeeze their eyes with resultant 33 
Bell’s reflex and supraduction.  Those who inject in the inferior hemisphere often find 34 
good exposure.  Further, the upward gaze required by inferior hemisphere injection thins 35 
the inferior tear film, theoretically decreasing the concentration of bacteria8.  On the other 36 
hand, other ocular surgeries, such as inferiorly placed trabeculectomies, carry an 37 
increased risk of endophthalmitis compared to those placed superiorly32, 33, a finding 38 
attributed to the bacteria-rich tear film34.  Roth and colleagues35 reported a greater risk of 39 
endophthalmitis after inferior hemisphere injection compared to those in the superior 40 
hemisphere among 10,834 consecutive injections.  Our study found no difference in 41 
endophthalmitis risk between superior and inferior hemisphere injections, suggesting 42 
either hemisphere is acceptable.   43 
Some vitreoretinal specialists displace the conjunctiva with a sterile cotton tip 44 
applicator when injecting through the pars plana in an effort to avoid a straight tract for 45 
bacteria to enter through the conjunctiva and sclera into the vitreous cavity36.  Others 46 
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argue it is best to minimize manipulation of the ocular surface to decrease risk of 1 
potential contamination.  In our study, there was no difference in endophthalmitis risk 2 
between those who do and do not displace conjunctiva while injecting.   3 
There was no difference in endophthalmitis risk after bevacizumab or 4 
ranibizumab injection in our study, similar to the findings of other studies6, 8.  Given the 5 
wide confidence intervals, however, we cannot draw strong conclusions from this result.  6 
Our study has several limitations.  Although we identified and recorded 7 
endophthalmitis cases prospectively with an infection surveillance program, a method we 8 
feel is more accurate than retrospective identification, it is possible that we 9 
underestimated risk of endophthalmitis. We retrospectively reviewed charts at the end of 10 
the surveillance period, which could have introduced certain biases and inaccuracies.  For 11 
example, our study utilized Snellen acuity, which is not as accurate as best-corrected 12 
visual acuity. Also, we were unable to assess other relevant risk factors, such as degree of 13 
blepharitis, because this was not systematically documented in the charts.  Our culture-14 
positivity rate of 30.4% was lower compared to other studies.  For example, the 15 
Endophthalmitis Vitrectomy Study  (EVS)37 reported that 66% of cases (138 of 202) 16 
undergoing tap and inject for endophthalmitis after cataract surgery were confirmed 17 
culture-positive.  Their higher rate of culture-positivity may be related to their 18 
methodology; they collected vitreous samples by either single port vitrectomy or needle 19 
aspiration whereas we only used needle apiration.  In our study, nine of 23 cases had an 20 
unsuccessful vitreous biopsy and thus had aqueous biopsy alone, and in the EVS, 21 
aqueous biopsy was associated with a lower confirmed laboratory infection rate (26.9%) 22 
compared to undiluted vitreous (58.9%)38.  23 
Another possible reason our culture-positivity rate was low could be that we 24 
included cases of presumed non-infectious endophthalmitis.  Intraocular inflammation is 25 
a known possible sequeale of intravitreal anti-VEGF injection10, 39.  Our standard practice 26 
is to administer intravitreal antibiotics whenever the examing physician feels that the case 27 
is more likely then non-infectious endophthalmitis.  28 
Because of the low incidence of endophthalmitis, our risk factor analysis is 29 
underpowered to find small differences.  It is possible that our risk factor results are 30 
subject to misclassification bias if the injecting vitreoretinal specialists deviated from 31 
their preferred injection technique during some injections. Further, there may have been 32 
undocumented variations in prepping technique in cases developing endophthalmitis. 33 
In summary, the risk of endophthalmitis after intravitreal anti-VEGF injection is 34 
low.  The accuracy of reported rates in the literature, in part, depends on individual study 35 
designs and the study’s definition of “endophthalmitis”.  Visual outcomes are good for 36 
most cases, with 83% to baseline visual acuity within three to six months.  However, a 37 
subgroup of infected eyes will have devastating visual outcomes.  The presence or 38 
absence of pain, vitritis, decreased vision, or hypopyon, and the interval between 39 
injection and presentation, does not help distinguish culture-positive from culture-40 
negative cases.  Thus, we recommend vitreoretinal specialists have a low threshold to 41 
perform emergent tap and injection of intravitreal antibiotics.  This study did not identify 42 
any modifiable risk factors to prevent endophthalmitis. The incidence endophthalmitis 43 
does not appear to be affected by use of a lid speculum, conjunctival displacement, 44 
hemisphere of injection, or use bevacizumab or ranbizumab.  45 
 46 
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